Cross Regulation of Sirtuin 1, AMPK, and PPARγ in Conjugated Linoleic Acid Treated Adipocytes

Shan Jiang; Wei Wang; Miner, Jess; Fromm, Michael
November 2012
PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1
Academic Journal
Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor γ (PPARγ) generally opposing these reductions. Sirtuin 1 (SIRT1), a histone/protein deacetylase that affects energy homeostasis, often functions coordinately with AMPK, and is capable of binding to PPARγ, thereby inhibiting its activity. This study investigated the role of SIRT1 in the response of 3T3-L1 adipocytes to 10c12 CLA by testing the following hypotheses: 1) SIRT1 is functionally required for robust TG reduction; and 2) SIRT1, AMPK, and PPARγ cross regulate each other. These experiments were performed by using activators, inhibitors, or siRNA knockdowns that affected these pathways in t10c12 CLA-treated 3T3-L1 adipocytes. Inhibition of SIRT1 amounts or activity using siRNA, sirtinol, nicotinamide, or etomoxir attenuated the amount of TG loss, while SIRT1 activator SRT1720 increased the TG loss. SRT1720 increased AMPK activity while sirtuin-specific inhibitors decreased AMPK activity. Reciprocally, an AMPK inhibitor reduced SIRT1 activity. Treatment with t10c12 CLA increased PPARγ phosphorylation in an AMPK-dependent manner and increased the amount of PPARγ bound to SIRT1. Reciprocally, a PPARγ agonist attenuated AMPK and SIRT1 activity levels. These results indicated SIRT1 increased TG loss and that cross regulation between SIRT1, AMPK, and PPARγ occurred in 3T3-L1 adipocytes treated with t10c12 CLA.


Related Articles

  • PEP programme on the money for HIV infections.  // PharmacoEconomics & Outcomes News;2/28/2004, Issue 447, p13 

    Provides information on a study regarding the cost-effectiveness of postexposure prophylaxis (PEP) for non-occupational exposure to HIV infections. Background on a PEP program used to assess the cost-effectiveness of an urban PEP intervention to prevent HIV infections after sexual or...

  • Comparing Cost-Effectiveness of HIV Testing Strategies: Targeted and Routine Testing in Washington, DC. Castel, Amanda D.; Choi, Sungwoog; Dor, Avi; Skillicorn, Jennifer; Peterson, James; Rocha, Nestor; Kharfen, Michael // PLoS ONE;10/14/2015, Vol. 10 Issue 10, p1 

    Background: Routine HIV testing is an essential approach to identifying undiagnosed infections, linking people to care and treatment, and preventing new infections. In Washington, DC, where HIV prevalence is 2.4%, a combination of routine and targeted testing approaches has been implemented...

  • Health Economics in HIV Disease: A Review of the European Literature. Youle, M.; Trueman, P.; Simpson, K. // PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1 

    The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the...

  • Universal Access to HIV Treatment versus Universal 'Test and Treat': Transmission, Drug Resistance & Treatment Costs. Wagner, Bradley G.; Blower, Sally; Cameron, D. William // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ∼1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal 'test and treat' (T&T) strategy to try to...

  • Initiating HAART earlier a prudent move in HIV infections.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p7 

    Presents information on a study which focused on the significance of the early initiation of highly active antiretroviral therapy among patients with HIV infections. Cost effectiveness of the strategy; Association of the strategy with quality-adjusted survival; Results of sensitivity analysis.

  • EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment. Vandewalle, Björn; Llibre, Josep M.; Parienti, Jean-Jacques; Ustianowski, Andrew; Camacho, Ricardo; Smith, Colette; Miners, Alec; Ferreira, Diana; Félix, Jorge // PLoS ONE;2/12/2016, Vol. 11 Issue 2, p1 

    The goal of this research was to establish a new and innovative framework for cost-effectiveness modeling of HIV-1 treatment, simultaneously considering both clinical and epidemiological outcomes. EPICE-HIV is a multi-paradigm model based on a within-host micro-simulation model for the disease...

  • Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006. Beck, Eduard J.; Mandalia, Sundhiya; Lo, Gary; Sharott, Peter; Youle, Mike; Anderson, Jane; Baily, Guy; Brettle, Ray; Fisher, Martin; Gompels, Mark; Kinghorn, George; Johnson, Margaret; McCarron, Brendan; Pozniak, Anton; Tang, Alan; Walsh, John; White, David; Williams, Ian; Gazzard, Brian // PLoS ONE;2011, Vol. 6 Issue 5, p1 

    Background: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line...

  • "Significant cost savings" accrued with discontinuation of HAART.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p9 

    Discusses research being done on cost saving and clinical outcome associated with the discontinuation of therapy in HIV patients. Reference to a study by P. Keiser and colleagues, presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment in July 2005;...

  • Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. Sanders, Gillian D.; Bayoumi, Ahmed M.; Sundaram, Vandana; Bilir, S. Pinar; Neukermans, Christopher P.; Rydzak, Chara E.; Douglass, Lena R.; Lazzeroni, Laura C.; Holodniy, Mark; Owens, Douglas K. // New England Journal of Medicine;2/10/2005, Vol. 352 Issue 6, p570 

    Background: The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined. Methods: We developed a Markov model of costs, quality of life, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics